Valeant Pharmaceuticals Intl Inc (VRX) : Black Maple Capital Management Lp added new position in Valeant Pharmaceuticals Intl Inc during the most recent quarter end. The investment management firm now holds 65,000 shares of Valeant Pharmaceuticals Intl Inc which is valued at $1,619,800 , the company said in a statement filed on Aug 15, 2016 with the SEC.Valeant Pharmaceuticals Intl Inc makes up approximately 4.15% of Black Maple Capital Management Lp’s portfolio.
Other Hedge Funds, Including , Parallax Volatility Advisers boosted its stake in VRX in the latest quarter, The investment management firm added 216,412 additional shares and now holds a total of 229,067 shares of Valeant Pharmaceuticals Intl Inc which is valued at $5,708,350. Valeant Pharmaceuticals Intl Inc makes up approx 0.26% of Parallax Volatility Advisers’s portfolio.Aperio Group reduced its stake in VRX by selling 7,301 shares or 20.51% in the most recent quarter. The Hedge Fund company now holds 28,291 shares of VRX which is valued at $705,012. Valeant Pharmaceuticals Intl Inc makes up approx 0.01% of Aperio Group’s portfolio.Parametric Portfolio Associates reduced its stake in VRX by selling 525,335 shares or 93.15% in the most recent quarter. The Hedge Fund company now holds 38,620 shares of VRX which is valued at $962,410. Atlantic Trust Group sold out all of its stake in VRX during the most recent quarter. The investment firm sold 40,851 shares of VRX which is valued $1,018,007. Meag Munich Ergo Kapitalanlagegesellschaft Mbh added VRX to its portfolio by purchasing 55,000 company shares during the most recent quarter which is valued at $1,226,500. Valeant Pharmaceuticals Intl Inc makes up approx 0.11% of Meag Munich Ergo Kapitalanlagegesellschaft Mbh’s portfolio.
Valeant Pharmaceuticals Intl Inc opened for trading at $28.91 and hit $29.385 on the upside on Thursday, eventually ending the session at $29.12, with a gain of 0.31% or 0.09 points. The heightened volatility saw the trading volume jump to 1,54,49,178 shares. Company has a market cap of $10,120 M.
On the company’s financial health, Valeant Pharmaceuticals Intl Inc reported $1.40 EPS for the quarter, missing the analyst consensus estimate by $ -0.08 based on the information available during the earnings call on Aug 9, 2016. Analyst had a consensus of $1.48. The company had revenue of $2420.20 million for the quarter, compared to analysts expectations of $2451.77 million. The company’s revenue was down -11.4 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $2.14 EPS.
Many Wall Street Analysts have commented on Valeant Pharmaceuticals Intl Inc. Company shares were Upgraded by Morgan Stanley on Aug 17, 2016 to ” Overweight”, Firm has raised the Price Target to $ 42 from a previous price target of $33 .Company shares were Upgraded by Mizuho on Aug 15, 2016 to ” Neutral”, Firm has raised the Price Target to $ 25 from a previous price target of $11 .Company shares were Reiterated by Piper Jaffray on Aug 10, 2016 to “Underweight”, Firm has raised the Price Target to $ 22 from a previous price target of $19 .
Valeant Pharmaceuticals International Inc. is a specialty pharmaceutical and medical device company. The Company is engaged in developing manufacturing and marketing a range of branded generic and branded generic pharmaceuticals over-the-counter (OTC) products and medical devices (contact lenses intraocular lenses ophthalmic surgical equipment and aesthetics devices) which are marketed directly or indirectly in over 100 countries. The Company operates through two segments: developed markets and emerging markets. The Company’s developed markets segment consists of sales in the United States of pharmaceutical products OTC products and medical device products. The Company’s Emerging Markets segment consists of branded generic pharmaceutical products and branded pharmaceuticals OTC products and medical device products.